CALR and chronic myelogenous leukemia, BCR-ABL1 positive: Targeted therapy driven towards a particular clonal population (mostly Ph +v CML) may suppress the former population and facilitate the emergence of the other relatively masked clonal (CALR mutated) population (19,20).